Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $48.69 down -0.33% from the previous closing price of $48.85. In other words, the price has decreased by -$0.33 from its previous closing price. On the day, 0.67 million shares were traded. JANX stock price reached its highest trading level at $49.1331 during the session, while it also had its lowest trading level at $46.45.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.80 and its Current Ratio is at 26.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 21, 2024, initiated with a Buy rating and assigned the stock a target price of $62.
On March 20, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.
On April 06, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $24.Wedbush initiated its Outperform rating on April 06, 2023, with a $24 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’23 when Avalon Ventures XI, L.P. bought 849,854 shares for $5.87 per share. The transaction valued at 4,988,643 led to the insider holds 849,854 shares of the business.
Reardon Tighe bought 849,854 shares of JANX for $4,988,643 on Nov 13 ’23. The Acting Chief Financial Officer now owns 849,854 shares after completing the transaction at $5.87 per share. On Nov 13 ’23, another insider, Lichter Jay, who serves as the Director of the company, bought 849,854 shares for $5.87 each. As a result, the insider paid 4,988,643 and bolstered with 849,854 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2515330304 and an Enterprise Value of 2195339776. For the stock, the TTM Price-to-Sale (P/S) ratio is 311.30 while its Price-to-Book (P/B) ratio in mrq is 6.54. Its current Enterprise Value per Revenue stands at 271.6 whereas that against EBITDA is -30.91.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $58.69, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 43.92%, while the 200-Day Moving Average is calculated to be 204.98%.
Shares Statistics:
Over the past 3-months, JANX traded about 889.98K shares per day on average, while over the past 10 days, JANX traded about 1181550 shares per day. A total of 46.25M shares are outstanding, with a floating share count of 34.43M. Insiders hold about 33.35% of the company’s shares, while institutions hold 57.73% stake in the company. Shares short for JANX as of 1711584000 were 3753826 with a Short Ratio of 4.22, compared to 1709164800 on 2898000. Therefore, it implies a Short% of Shares Outstanding of 3753826 and a Short% of Float of 15.52.
Earnings Estimates
Investors are keenly observing as Jaguar Health, Inc. analysts analyze and rate the current performance of Janux Therapeutics Inc (JANX) in the stock market.The consensus estimate for the next quarter is $3.18, with high estimates of $0.97 and low estimates of $48.69.
